ZD06519

ZD06519 is a novel camptothecin analog specifically designed as a payload for antibody-drug conjugates (ADCs). It acts as a topoisomerase I inhibitor and was selected from a panel of camptothecin derivatives for its moderate free payload potency (~1 nM), low hydrophobicity, strong bystander effect, robust plasma stability, and high monomeric ADC content. When conjugated to antibodies using clinically validated linkers (such as MC-GGFG), ZD06519 demonstrates impressive efficacy in preclinical models of HER2-positive and folate receptor alpha (FRα)-overexpressing tumors. The compound is being developed primarily for use in oncology-focused ADCs targeting various solid tumors[1][2][3][4][5][9].

Other names

7-Hydroxyethyl carbamate-(10Me-11F-Camptothecin)